Hirntumoren

Zusammenfassung

Die morphologische Bildgebung mit der Magnetresonanztomografie (MRT) ist heute das Verfahren der Wahl zur Diagnostik von Hirntumoren, erlaubt jedoch in vielen Situationen nur eine eingeschränkte Differenzierung des Tumorgewebes von unspezifischen Gewebsveränderungen. Die Positronen-Emissions-Tomografie (PET) und Single-Photonen-Emissions-Tomografie (SPECT) haben sich als leistungsfähige diagnostische Verfahren erwiesen, die bei unklaren Befunden in vielen Fällen zu einer weiteren Abklärung beitragen können. Insbesondere die Bildgebung mit Aminosäuren führt bei zerebralen Gliomen zu einer spezifischeren Darstellung der Ausdehnung des soliden Gliomgewebes, welche bei der Planung einer Biopsie, eines neurochirurgischen Eingriffs und einer Bestrahlung entscheidende Hilfestellung bieten kann. Des Weiteren können Tumorrezidive von posttherapeutischen Veränderungen besser differenziert, wertvolle prognostische Informationen bei niedriggradigen Gliomen gewonnen und Therapieeffekte frühzeitig beurteilt werden.

Abstract

Magnetic Resonance Tomography (MRT) is the method of choice for the diagnostics of cerebral gliomas, but the differentiation of tumour tissue from unspecific tissue changes is limited. Positron emission tomography (PET) and Single-Photon-Emission-Computed Tomography (SPECT) may offer relevant additional information which allows for a more accurate diagnostics in unclear situations. Especially, radiolabeled amino acids offer a better delineation of cerebral gliomas which allows an improved guidance of biopsy, planning of surgery and radiation therapy. Furthermore, amino acid imaging appears to be useful to differentiate tumor recurrence from unspecific posttherapeutic tissue, to predict the prognosis especially in low grade gliomas and to monitor the metabolic response during tumor therapy.

PET - SPECT - Hirntumoren - FDG - Aminosäuren - ²⁰¹Tl - ^99mTc-Sestamibi - ^99mTc-Tetrofosmin

PET - SPECT - brain tumors - FDG - amino acids - ²⁰¹Tl - ^99mTc-Sestamibi - ^99mTc-Tetrofosmin

Literatur

• 1 Beauchesne P, Pedeux R, Boniol M, Soler C. ^99mTc-Sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma.  J Nucl Med. 2004;  45 409-413
• 2 Chaskis C, Stadnik T, Michotte A, Van Rompaey K, D’Haens J. Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study.  Acta Neurochir. 2006;  148 277-285
• 3 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps M E, Silverman D H. Imaging proliferation in brain tumors with ¹⁸F-FLT PET: comparison with ¹⁸F-FDG.  J Nucl Med. 2005;  46 945-952
• 4 Cher L M, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, O’Keefe G J, Sachinidis J I, Berlangieri S U, Fabinyi G, Scott A M. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using ¹⁸F-fluoromisonidazole, ¹⁸F-FDG PET, and immunohistochemical studies.  J Nucl Med. 2006;  47 410-418
• 5 Choi J Y, Kim S E, Shin H J, Kim B T, Kim J H. Brain tumor imaging with ^99mTc-tetrofosmin: comparison with ²⁰¹Tl, ^99mTc-MIBI, and ¹⁸F-fluorodeoxyglucose.  J Neurooncol. 2000;  46 63-70
• 6 De Herder W W, Reijs A E, Feelders R A, van Aken M O, Krenning E P, van der Lely A J, Kwekkeboom D J. Diagnostic imaging of dopamine receptors in pituitary adenomas.  Eur J Endocrinol. 2007;  156 Suppl 1 53-56
• 7 Del Sole A, Falini A, Ravasi L, Ottobrini L, De Marchis D, Bombardieri E, Lucignani G. Anatomical and biochemical investigation of primary brain tumours.  Eur J Nucl Med. 2001;  28 1851-1872
• 8 Derlon J M. The in vivo metabolic investigation of brain gliomas with positron emission tomography.  Adv Tech Stand Neurosurg. 1998;  24 Review 41-76
• 9 Ernst S. Hirntumoren. In: Heindel W, Kugel H, Lackner K (eds). Rationelle MR-Untersuchungstechniken. Thieme Verlag Stuttgart 1997; 3-7
• 10 Floeth F, Pauleit D, Wittsack H J, Langen K J, Reifenberger G, Hamacher K, Müller H W, Zilles K, Messing-Jünger M, Weber F, Stummer W, Steiger H J, Coenen H H, Sabel M. Multimodal metabolic imaging of cerebral gliomas using positron emission tomography with [¹⁸F]-fluoroethyl-l-tyrosine and magnetic resonance spectroscopy.  J Neurosurgery. 2005;  102 318-327
• 11 Floeth F W, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider M J, Jansen P, Hamacher K, Coenen H H, Stummer W, Steiger H J, Langen K J. Prognostic value of O-(2-¹⁸F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.  J Nucl Med. 2007;  48 519-527
• 12 Galldiks N, Kracht L W, Burghaus L, Thomas A, Jacobs A H, Heiss W D, Herholz K. Use of ¹¹C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.  Eur J Nucl Med Mol Imaging. 2006;  33 516-524
• 13 Gomez-Rio M, Martinez Del Valle Torres D, Rodriguez-Fernandez A, Llamas-Elvira J M, Lozano S O, Font C R, Lopez Ramirez E, Katati M. ⁽²⁰¹⁾Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis.  Eur J Nucl Med Mol Imaging. 2004;  31 1237-1243
• 14 Grosu A L, Feldmann H, Dick S. et al . Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas.  Int J Radiat Oncol Biol Phys. 2002;  54 842-854
• 15 Grosu A L, Weber W A, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C. Reirradiation of recurrent high-grade gliomas using amino acid PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.  Int J Radiat Oncol Biol Phys. 2005;  63 511-519
• 16 Henze M, Mohammed A, Schlemmer H P, Herfarth K K, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis.  J Nucl Med. 2004;  45 579-586
• 17 Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss L G, Doll J, Macke H R, Eisenhut M, Debus J, Haberkorn U. Characterization of ⁶⁸Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.  J Nucl Med. 2005;  46 763-769
• 18 Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus R I, Mendoza G, Weber-Luxemburger G, Löttgen J, Thiel A, Wienhard K Heiss W D. ¹¹C-methionine PET for differential diagnosis of low-grade-gliomas.  Neurology. 1998;  50 1316-1322
• 19 Jacobs A H, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, Kaestle C, Wagner R, Wienhard K, Heiss W D. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas.  Lancet. 2001;  358 727-729
• 20 Jacobs A H, Kracht L W, Gossmann A. et al . Imaging in neurooncology.  NeuroRx. 2005;  2 Review 333-347
• 21 Jacobs A H, Thomas A, Kracht L W, Li H, Dittmar C, Garlip G, Galldiks N, Klein J C, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss W D. ¹⁸F-fluoro-L-thymidine and ¹¹C-methylmethionine as markers of increased transport and proliferation in brain tumors.  J Nucl Med. 2005;  46 1948-1958
• 22 Jager P L, Vaalburg W, Pruim J, de Vries E G, Langen K J, Piers D A. Radiolabeled amino acids: basic aspects and clinical applications in oncology.  J Nucl Med. 2001;  42 432-445
• 23 Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G. et al . Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.  J Nucl Med. 1998;  39 778-785
• 24 Kracht L W, Miletic H, Busch S, Jacobs A H, Voges J, Hoevels M, Klein J C, Herholz K, Heiss W D. Delineation of brain tumor extent with [¹¹C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.  Clin Cancer Res. 2004;  10 7163-7170
• 25 Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine.  J Nucl Med. 1998;  39 23-27
• 26 Lanfermann H, Herminghaus S, Pilatus U, Hattingen E, Zanella F E. Bedeutung der ¹H-MR-Spektroskopie bei der Differenzialdiagnose und Graduierung intrakranieller Tumoren.  Dtsch Arztebl. 2004;  101 A649-A655
• 27 Langen K J, Pauleit D, Coenen H H. [¹²³I]Iodo-α-Methyl-L-Tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2002;  29 625-631
• 28 Langen K -J. Amino Acid Transport Studies in Brain Tumors. In: Molecular Nuclear Medicine - The Challenge of Genomics and Proteomics to Clinical Practice. In: Feinendegen LE, Shreeve WW, Eckelman WC, Bahk Y-W, Wagner Jr HN (eds). Springer-Verlag Berlin, Heidelberg 2003, S. 477-485
• 29 Langen K J, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen H H, Pauleit D. O-(2-[¹⁸F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2006;  33 287-294
• 30 Le Jeune F P, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies.  J Neurooncol. 2006;  77 177-183
• 31 Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, Sasaki T. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging.  Eur J Nucl Med. 2001;  28 1664-1670
• 32 Pauleit D, Langen K J, Floeth F W, Hautzel H, Riemenschneider M J, Reifenberger G, Shah J, Müller H W. Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas?.  J Magn Reson Imaging. 2004;  20 758-764
• 33 Pauleit D, Floeth F, Hamacher K, Riemenschneider M J, Reifenberger G, Müller H W, Zilles K, Coenen H H, Langen K J. O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET combined with Magnetic Resonance Imaging Improves the Diagnostic Assessment of Cerebral Gliomas.  Brain. 2005;  128 678-687
• 34 Plotkin M, Eisenacher J, Bruhn H, Wurm R, Michel R, Stockhammer F, Feussner A, Dudeck O, Wust P, Felix R, Amthauer H. ¹²³I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study.  J Neurooncol. 2004;  70 49-58
• 35 Pöpperl G, Gotz C, Rachinger W, Schnell O, Gildehaus F J, Tonn J C, Tatsch K. Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.  Eur J Nucl Med Mol Imaging. 2006;  33 792-800
• 36 Pöpperl G, Kreth F W, Herms J, Koch W, Mehrkens J H, Gildehaus F J, Kretzschmar H A, Tonn J C, Tatsch K. Analysis of ¹⁸F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?.  J Nucl Med. 2006;  47 393-403
• 37 Prigent-Le Jeune F, Dubois F, Perez S, Blond S, Steinling M. Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation of response to chemotherapy: first results.  Eur J Nucl Med Mol Imaging.. 2004;  31 714-719
• 38 Rachinger W, Goetz C, Pöpperl G, Gildehaus F J, Kreth F W, Holtmannspotter M, Herms J, Koch W, Tatsch K, Tonn J C. Positron emission tomography with O-(2-[¹⁸F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.  Neurosurgery. 2005;  57 505-511
• 39 Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, Bolander H, Bergstrom M, Smits A. Positron emission tomography (¹¹)C-methionine and survival in patients with low-grade gliomas.  Cancer. 2001;  92 1541-1549
• 40 Ricci P E, Karis J P, Heiserman J E, Fram E K, Bice A N, Drayer B P. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?.  Am J Neuroradiol. 1998;  19 407-413
• 41 Salber D, Stoffels G, Pauleit D, Reifenberger G, Sabel M, Shah N J, Hamacher K, Coenen H H, Langen K J. Differential uptake of ¹⁸F-FET and ³H-L-methionine in focal cortical ischemia.  Nucl Med Biol. 2006;  33 1029-1035
• 42 Saleem A, Brown G D, Brady F, Aboagye E O, Osman S, Luthra S K, Ranicar A S, Brock C S, Stevens M F, Newlands E, Jones T, Price P. Metabolic activation of temozolomide measured in vivo using positron emission tomography.  Cancer Res. 2003;  63 2409-2415
• 43 Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors.  Semin Nucl Med. 2007;  37 Review 34-47
• 44 Semba T, Sugawara Y, Ochi T, Fujii T, Mochizuki T, Ohnishi T. Thallium-201 SPECT in prognostic assessment of malignant gliomas treated with postoperative radiotherapy.  Ann Nucl Med. 2006;  20 287-294
• 45 Sun D, Liu Q, Liu W, Hu W. Clinical application of ²⁰¹Tl SPECT imaging of brain tumors.  J Nucl Med. 2000;  41 5-10
• 46 Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L. Direct comparison of ¹⁸F-FDG and ¹¹C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.  Eur J Nucl Med Mol Imaging. 2005;  32 39-51
• 47 Vos M J, Berkhof J, Postma T J, Hoekstra O S, Barkhof F, Heimans J J. Thallium-201 SPECT: the optimal prediction of response in glioma therapy.  Eur J Nucl Med Mol Imaging. 2006;  33 222-227
• 48 Weckesser M, Langen K J, Rickert C H, Kloska S, Straeter R, Hamacher K, Kurlemann G, Wassmann H, Coenen H H, Schober O. Initial experiences with O-(2-[¹⁸F]fluorethyl)-L-tyrosine PET in the evaluation of primary brain tumors.  Eur J Nucl Med. 2005;  32 422-429